These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 17168761)

  • 21. Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease.
    Shie JJ; Fang JM; Kuo CJ; Kuo TH; Liang PH; Huang HJ; Yang WB; Lin CH; Chen JL; Wu YT; Wong CH
    J Med Chem; 2005 Jun; 48(13):4469-73. PubMed ID: 15974598
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Application of bioinformatics in search for cleavable peptides of SARS-CoV M(pro) and chemical modification of octapeptides.
    Du Q; Wang S; Jiang Z; Gao W; Li Y; Wei D; Chou KC
    Med Chem; 2005 May; 1(3):209-13. PubMed ID: 16787316
    [TBL] [Abstract][Full Text] [Related]  

  • 23. "Teaching old drugs to kill new bugs": structure-based discovery of anti-SARS drugs.
    Rajnarayanan RV; Dakshanamurthy S; Pattabiraman N
    Biochem Biophys Res Commun; 2004 Aug; 321(2):370-8. PubMed ID: 15358186
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural basis of inhibition specificities of 3C and 3C-like proteases by zinc-coordinating and peptidomimetic compounds.
    Lee CC; Kuo CJ; Ko TP; Hsu MF; Tsui YC; Chang SC; Yang S; Chen SJ; Chen HC; Hsu MC; Shih SR; Liang PH; Wang AH
    J Biol Chem; 2009 Mar; 284(12):7646-55. PubMed ID: 19144641
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease.
    Zhu L; George S; Schmidt MF; Al-Gharabli SI; Rademann J; Hilgenfeld R
    Antiviral Res; 2011 Nov; 92(2):204-12. PubMed ID: 21854807
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication.
    Ratia K; Pegan S; Takayama J; Sleeman K; Coughlin M; Baliji S; Chaudhuri R; Fu W; Prabhakar BS; Johnson ME; Baker SC; Ghosh AK; Mesecar AD
    Proc Natl Acad Sci U S A; 2008 Oct; 105(42):16119-24. PubMed ID: 18852458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A mechanistic view of enzyme inhibition and peptide hydrolysis in the active site of the SARS-CoV 3C-like peptidase.
    Yin J; Niu C; Cherney MM; Zhang J; Huitema C; Eltis LD; Vederas JC; James MN
    J Mol Biol; 2007 Aug; 371(4):1060-74. PubMed ID: 17599357
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structure of M
    Jin Z; Du X; Xu Y; Deng Y; Liu M; Zhao Y; Zhang B; Li X; Zhang L; Peng C; Duan Y; Yu J; Wang L; Yang K; Liu F; Jiang R; Yang X; You T; Liu X; Yang X; Bai F; Liu H; Liu X; Guddat LW; Xu W; Xiao G; Qin C; Shi Z; Jiang H; Rao Z; Yang H
    Nature; 2020 Jun; 582(7811):289-293. PubMed ID: 32272481
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovering severe acute respiratory syndrome coronavirus 3CL protease inhibitors: virtual screening, surface plasmon resonance, and fluorescence resonance energy transfer assays.
    Chen L; Chen S; Gui C; Shen J; Shen X; Jiang H
    J Biomol Screen; 2006 Dec; 11(8):915-21. PubMed ID: 17092912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure-based virtual screening against SARS-3CL(pro) to identify novel non-peptidic hits.
    Mukherjee P; Desai P; Ross L; White EL; Avery MA
    Bioorg Med Chem; 2008 Apr; 16(7):4138-49. PubMed ID: 18343121
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Only one protomer is active in the dimer of SARS 3C-like proteinase.
    Chen H; Wei P; Huang C; Tan L; Liu Y; Lai L
    J Biol Chem; 2006 May; 281(20):13894-8. PubMed ID: 16565086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease.
    Shao YM; Yang WB; Kuo TH; Tsai KC; Lin CH; Yang AS; Liang PH; Wong CH
    Bioorg Med Chem; 2008 Apr; 16(8):4652-60. PubMed ID: 18329272
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design and synthesis of cinanserin analogs as severe acute respiratory syndrome coronavirus 3CL protease inhibitors.
    Yang Q; Chen L; He X; Gao Z; Shen X; Bai D
    Chem Pharm Bull (Tokyo); 2008 Oct; 56(10):1400-5. PubMed ID: 18827378
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Severe acute respiratory syndrome coronavirus 3C-like proteinase N terminus is indispensable for proteolytic activity but not for enzyme dimerization. Biochemical and thermodynamic investigation in conjunction with molecular dynamics simulations.
    Chen S; Chen L; Tan J; Chen J; Du L; Sun T; Shen J; Chen K; Jiang H; Shen X
    J Biol Chem; 2005 Jan; 280(1):164-73. PubMed ID: 15507456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies.
    Tsai KC; Chen SY; Liang PH; Lu IL; Mahindroo N; Hsieh HP; Chao YS; Liu L; Liu D; Lien W; Lin TH; Wu SY
    J Med Chem; 2006 Jun; 49(12):3485-95. PubMed ID: 16759091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluating the 3C-like protease activity of SARS-Coronavirus: recommendations for standardized assays for drug discovery.
    Grum-Tokars V; Ratia K; Begaye A; Baker SC; Mesecar AD
    Virus Res; 2008 Apr; 133(1):63-73. PubMed ID: 17397958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dissection study on the severe acute respiratory syndrome 3C-like protease reveals the critical role of the extra domain in dimerization of the enzyme: defining the extra domain as a new target for design of highly specific protease inhibitors.
    Shi J; Wei Z; Song J
    J Biol Chem; 2004 Jun; 279(23):24765-73. PubMed ID: 15037623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Isatin compounds as noncovalent SARS coronavirus 3C-like protease inhibitors.
    Zhou L; Liu Y; Zhang W; Wei P; Huang C; Pei J; Yuan Y; Lai L
    J Med Chem; 2006 Jun; 49(12):3440-3. PubMed ID: 16759084
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heteroaromatic ester inhibitors of hepatitis A virus 3C proteinase: Evaluation of mode of action.
    Huitema C; Zhang J; Yin J; James MN; Vederas JC; Eltis LD
    Bioorg Med Chem; 2008 May; 16(10):5761-77. PubMed ID: 18407505
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibitors of SARS-3CLpro: virtual screening, biological evaluation, and molecular dynamics simulation studies.
    Mukherjee P; Shah F; Desai P; Avery M
    J Chem Inf Model; 2011 Jun; 51(6):1376-92. PubMed ID: 21604711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.